Cover Image

Brain‐derived tau to measure treatment effect in Alzheimer's disease and frontotemporal dementia

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Cassandra Marotta, Fernando Gonzalez‐Ortiz, Michael Turton, Henrik Zetterberg, Peter Harrison, Christopher M. Hovens, Benjamin Sinclair, Terence J. O'Brien, Kaj Blennow, Lucy Vivash
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Commentary on “It is time to share Alzheimer biomarker results in dementia with Lewy bodies”
by: John T. O'Brien
Published: (2025)

Examining the propensity and nature of criminal risk behaviours in frontotemporal dementia syndromes and Alzheimer's disease
by: Fiona Kumfor, et al.
Published: (2024)

Longitudinal changes in functional capacity in frontotemporal dementia and Alzheimer's disease
by: David Foxe, et al.
Published: (2024)

Association between BrainAGE and Alzheimer's disease biomarkers
by: Yousaf Abughofah, et al.
Published: (2025)

Preclinical dementia rating scores are associated with plasma phosphorylated tau‐217
by: Qi Huang, et al.
Published: (2025)

Microstructural alterations in the locus coeruleus‐entorhinal cortex pathway in Alzheimer's disease and frontotemporal dementia
by: Giulia Quattrini, et al.
Published: (2024)

Day‐to‐day sleep variability with Alzheimer's biomarkers in at‐risk elderly
by: Andrée‐Ann Baril, et al.
Published: (2024)

A Bayesian analysis of diagnostic timelines across Alzheimer's disease, frontotemporal dementia, and other neurodegenerative conditions
by: Ananthan Ambikairajah, et al.
Published: (2025)

Clinical and neuropathological associations of plasma Aβ42/Aβ40, p‐tau217 and neurofilament light in sporadic frontotemporal dementia spectrum disorders
by: Binita Rajbanshi, et al.
Published: (2025)

Autonomic dysfunction and hypothalamic atrophy in frontotemporal dementia and primary psychiatric disorders
by: Yannick S. S. Timar, et al.
Published: (2026)

Impairments in knowledge of social norms in presymptomatic, prodromal, and symptomatic frontotemporal dementia
by: Liset de Boer, et al.
Published: (2024)

Tracking clinical and neuroimaging progression of Alzheimer's disease by longitudinal trajectories of plasma biomarkers
by: Frederikke Kragh Clemmensen, et al.
Published: (2026)

Reduced plasma hexosylceramides in frontotemporal dementia are a biomarker of white matter integrity
by: Oana C. Marian, et al.
Published: (2025)

Accuracy of clinical diagnosis of behavioral variant frontotemporal dementia: A systematic review and meta‐analysis
by: Daniele Urso, et al.
Published: (2026)

Ethics of disclosure of onset‐predictive biomarker test results for genetic frontotemporal dementia in the research context
by: Charlotte H. Graafland, et al.
Published: (2025)

Automated analysis of expressive prosody in Dutch patients with behavioral variant frontotemporal dementia and primary progressive aphasia
by: Lize C. Jiskoot, et al.
Published: (2026)

Network‐based cortical atrophy predicts longitudinal clinical decline in sporadic behavioral variant frontotemporal dementia
by: Yuta Katsumi, et al.
Published: (2026)

Association of plasma GFAP with elevated brain amyloid is dependent on severity of white matter lesions in an Asian cognitively impaired cohort
by: Joyce R. Chong, et al.
Published: (2024)

Diagnostic utility of plasma p‐tau217 differs by Alzheimer's disease tau‐based subtypes
by: Seyed Hani Hojjati, et al.
Published: (2025)

Clinical and demographic factors modify the association between plasma phosphorylated tau‐181 and cognition
by: Corey J. Bolton, et al.
Published: (2024)

Cross‐sectional study of plasma phosphorylated tau 217 in persons without dementia
by: Toni T. Saari, et al.
Published: (2025)

Investigating the relationship between sleep disturbances and white matter hyperintensities in older adults on the Alzheimer's disease spectrum
by: Farooq Kamal, et al.
Published: (2024)

Relationship of plasma biomarkers to digital cognitive tests in Alzheimer's disease
by: Sofia Toniolo, et al.
Published: (2024)

Elevated tau in the piriform cortex in Alzheimer's but not Parkinson's disease using PET‐MR
by: Hossein Moein Taghavi, et al.
Published: (2024)

Identifying cognitive test scores associated with early tau burden in Alzheimer's disease
by: Caitlin M. Terao, et al.
Published: (2025)

Aβ oligomers peak in early stages of Alzheimer's disease preceding tau pathology
by: Lara Blömeke, et al.
Published: (2024)

Plasma p‐tau217 and APOE genotype: Prodromal Alzheimer's disease staging
by: Ann M. Stowe, et al.
Published: (2026)

Exploring neuropsychiatric and behavioral symptoms, and social cognitive deficits in the differential diagnosis of behavioral variant of frontotemporal dementia and primary psychiatric disorders: A systematic literature review
by: Femke G. van Dijk, et al.
Published: (2026)

The association between multiple long‐term conditions and dementia: A UK cohort study
by: Hilary Shepherd, et al.
Published: (2025)

Resistance and resilience to tau pathology in Alzheimer's disease: Effects of age, sex, and APOE alleles
by: Yury Loika, et al.
Published: (2024)

Correction to “Aβ oligomers peak in early stages of Alzheimer's disease preceding tau pathology”
Published: (2024)

Clinical performance of the fully automated Lumipulse plasma p‐tau217 assay in mild cognitive impairment and mild dementia
by: Adam H. Dyer, et al.
Published: (2025)

Delphi consensus guidelines for the use of striatal dopaminergic imaging and cardiac metaiodobenzylguanidine (MIBG) scintigraphy for the diagnosis of dementia and mild cognitive impairment with Lewy bodies
by: Paul C. Donaghy, et al.
Published: (2026)

Racial/ethnic differences in neuropsychological test performance in frontotemporal degeneration
by: Melanie A. Matyi, et al.
Published: (2025)

Comparison of three plasma p‐tau217 assays to detect PET‐confirmed Alzheimer's pathologies
by: Sayo Matsuura, et al.
Published: (2026)

Associations of plasma phosphorylated tau217 with cognitive impairment and brain microstructural alterations in Alzheimer's disease
by: Miguel Ángel Rivas‐Fernández, et al.
Published: (2026)

Plasma p‐tau217 for Alzheimer's disease diagnosis: a memory clinic implementation approach
by: Giorgia Brodini, et al.
Published: (2026)

Navigating late‐stage dementia: A perspective from the Alzheimer's Association
by: Kristen Clifford, et al.
Published: (2024)

Poor dream recall associates with Alzheimer's disease biomarkers and dementia risk
by: Darren M. Lipnicki, et al.
Published: (2026)

Sensory changes in preclinical, prodromal, and clinical Alzheimer's disease and related dementias
by: Willa D. Brenowitz, et al.
Published: (2026)